Benefits and risks of anthracyclines in early-stage breast cancer

Lancet. 2024 Mar 30;403(10433):1239-1240. doi: 10.1016/S0140-6736(23)02889-1.

Authors

Fernando Kude de Almeida¹, Frederico Soares Falcetta², Daniela Dornelles Rosa³

Affiliations

¹ Division of Oncology, Hospital Femina, Porto Alegre 90430, Brazil. Electronic address: fernandokude@gmail.com.
² Division of Clinical Pathology, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.
³ Department of Internal Medicine, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.

PMID: 38555132
DOI: 10.1016/S0140-6736(23)02889-1

No abstract available

Publication types

Letter
Comment

MeSH terms

Anthracyclines / adverse effects
Antibiotics, Antineoplastic
Antineoplastic Combined Chemotherapy Protocols
Breast Neoplasms* / drug therapy
Chemotherapy, Adjuvant
Female
Humans
Risk Assessment
Taxoids / therapeutic use

Substances

Anthracyclines
Antibiotics, Antineoplastic
Taxoids